Novo Nordisk A/S
Bagsværd, Denmark, 6 August 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
DÉSIRÈE JANTZEN ASGREEN
2
Reason for the notification
a)
Position/status
Member of the Board of Directors
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Other transaction (vesting of shares in
accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 294.30
74
d)
Aggregated information
74 shares
DKK 21,778.20
e)
Date of the transaction
2026-08-05
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
ELISABETH DAHL CHRISTENSEN
2
Reason for the notification
a)
Position/status
Member of the Board of Directors
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Other transaction (vesting of shares in
accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 294.30
74
d)
Aggregated information
74 shares
DKK 21,778.20
e)
Date of the transaction
2026-08-05
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
METTE BØJER JENSEN
2
Reason for the notification
a)
Position/status
Member of the Board of Directors
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Other transaction (vesting of shares in
accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 294.30
74
d)
Aggregated information
74 shares
DKK 21,778.20
e)
Date of the transaction
2026-08-05
f)
Place of the transaction
Outside a trading venue
Story continues
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
SEMSI KILIC MADSEN
2
Reason for the notification
a)
Position/status
Member of the Board of Directors
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Other transaction (vesting of shares in
accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 294.30
74
d)
Aggregated information
74 shares
DKK 21,778.20
e)
Date of the transaction
2026-08-05
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
EMIL KONGSHØJ LARSEN
2
Reason for the notification
a)
Position/status
Executive Vice President, International Operations
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Other transaction (vesting of shares in
accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 294.30
74
d)
Aggregated information
74 shares
DKK 21,778.20
e)
Date of the transaction
2026-08-05
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
KARSTEN MUNK KNUDSEN
2
Reason for the notification
a)
Position/status
Executive Vice President, Chief Financial Officer (CFO)
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Other transaction (vesting of shares in
accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 294.30
74
d)
Aggregated information
74 shares
DKK 21,778.20
e)
Date of the transaction
2026-08-05
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
KASPER BØDKER MEJLVANG
2
Reason for the notification
a)
Position/status
Executive Vice President, Global Manufacturing & Supply
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Other transaction (vesting of shares in
accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 294.30
74
d)
Aggregated information
74 shares
DKK 21,778.20
e)
Date of the transaction
2026-08-05
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
MAZIAR MIKE DOUSTDAR
2
Reason for the notification
a)
Position/status
President and CEO
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Other transaction (vesting of shares in
accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 294.30
74
d)
Aggregated information
74 shares
DKK 21,778.20
e)
Date of the transaction
2026-08-05
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
MARTIN HOLST LANGE
2
Reason for the notification
a)
Position/status
Executive Vice President, R&D and Chief Scientific Officer (CSO)
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Other transaction (vesting of shares in
accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 294.30
74
d)
Aggregated information
74 shares
DKK 21,778.20
e)
Date of the transaction
2026-08-05
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
THILDE GYNTHE BØGEBJERG KRØYER
2
Reason for the notification
a)
Position/status
Executive Vice President, Enterprise IT & Quality
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Other transaction (vesting of shares in
accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 294.30
74
d)
Aggregated information
74 shares
DKK 21,778.20
e)
Date of the transaction
2026-08-05
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
TANIA SABROE
2
Reason for the notification
a)
Position/status
Executive Vice President, People, Organisation & Corporate Affairs
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Other transaction (vesting of shares in
accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 294.30
74
d)
Aggregated information
74 shares
DKK 21,778.20
e)
Date of the transaction
2026-08-05
f)
Place of the transaction
Outside a trading venue
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,700 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
Company announcement No 49 / 2026
Attachment